Prices delayed ≤15 min
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat
Frequently Asked Questions about ABBV
What does AbbVie Inc. (ABBV) do?
AbbVie Inc. is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and selling a range of medications. Notable products include HUMIRA, which treats autoimmune diseases, and SKYRIZI, aimed at moderate to severe plaque psoriasis. The company is a key player in the healthcare sector, specifically within the drug manufacturing industry.
Is ABBV stock a good investment in 2026?
Considering AbbVie's revenue growth of 8.6% and a solid market capitalization of $406.42 billion, it shows potential for continued performance. However, without a P/E ratio or EPS data, it's challenging to assess its valuation fully. Investors should weigh these growth metrics against broader market conditions and company-specific developments.
What is AbbVie Inc.'s market capitalisation and stock price?
As of now, AbbVie Inc. has a market capitalization of $406.42 billion and a stock price of $229.98. This price is positioned between its 52-week high of $244.81 and low of $164.39, indicating a relatively stable performance within the past year.
Does ABBV pay dividends to shareholders?
AbbVie does not currently pay dividends to its shareholders. Instead, the company appears to be reinvesting its profits into growth opportunities, as evidenced by its substantial free cash flow of $17.82 billion.
How profitable is AbbVie Inc.?
AbbVie Inc. reported a net income of $4.23 billion, resulting in a net margin of 6.9%. While ROE data is not available, the company's free cash flow of $17.82 billion suggests strong profitability and cash generation capabilities.
What is ABBV's P/E ratio and is the stock overvalued?
AbbVie does not currently have a P/E ratio listed, which complicates direct valuation comparisons. Within the healthcare sector, a lack of earnings data may suggest caution, but the company's revenue growth could indicate potential value if future earnings are realized.
How much debt does AbbVie Inc. have?
AbbVie Inc. has not disclosed its debt-to-equity ratio, indicating that specific debt information is unavailable. However, with a current ratio of 0.67, it suggests that the company may have limited short-term liquidity, which could be a concern for some investors.
What is ABBV's 52-week trading range?
ABBV's stock has traded between $164.39 and $244.81 over the past year. Currently, at $229.98, the stock is near its 52-week high and above its 50-day moving average of $226.61, suggesting strong recent performance.
Is ABBV a growth stock or value stock?
With a revenue growth rate of 8.6%, AbbVie leans towards being a growth stock, particularly in the pharmaceutical sector. However, without EPS data, it is difficult to assess its full growth potential or compare it against typical value metrics.
What are the main risks of investing in ABBV?
Investing in ABBV carries risks such as its low beta of 0.35, indicating less volatility compared to the market, which could limit upside potential. Additionally, the absence of dividend payments and competition in the drug manufacturing industry present ongoing challenges that investors should consider.